EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 172 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2017. The put-call ratio across all filers is 0.91 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $2,018,000 | -28.7% | 47,508 | -19.4% | 0.42% | -25.1% |
| Q2 2020 | $2,830,000 | -30.3% | 58,977 | -33.2% | 0.56% | -10.3% |
| Q1 2020 | $4,061,000 | -60.2% | 88,273 | -48.1% | 0.63% | -35.5% |
| Q4 2019 | $10,214,000 | -26.2% | 170,008 | -30.5% | 0.98% | -6.8% |
| Q3 2019 | $13,842,000 | +22.7% | 244,695 | +20.7% | 1.05% | +29.7% |
| Q2 2019 | $11,284,000 | +73.3% | 202,652 | +57.2% | 0.81% | +70.3% |
| Q1 2019 | $6,510,000 | -99.9% | 128,945 | -4.9% | 0.47% | +7.5% |
| Q4 2018 | $5,461,471,000 | -32.9% | 135,554 | +15.5% | 0.44% | -16.0% |
| Q3 2018 | $8,136,846,000 | +435.5% | 117,364 | +484.4% | 0.52% | +377.3% |
| Q2 2018 | $1,519,480,000 | +629.2% | 20,083 | +407.8% | 0.11% | +587.5% |
| Q1 2018 | $208,389,000 | -97.4% | 3,955 | -96.2% | 0.02% | -97.9% |
| Q2 2017 | $8,160,697,000 | +2757.3% | 103,444 | +3111.5% | 0.76% | +1655.8% |
| Q4 2015 | $285,606,000 | – | 3,221 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |